Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Fumigant 93 × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1 Lymphoid 1 Gastrointestinal 1 Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1016 Cisplatin 789 Pemetrexed 733 pembrolizumab 535 Paclitaxel 524 Docetaxel 479 Gemcitabine 366 Radiotherapy 337 Erlotinib Hydrochloride 334 Bevacizumab 292 Nivolumab 283 Etoposide 263 durvalumab 235 Drug Therapy 205 osimertinib 190 atezolizumab 182 Radiosurgery 163 Gefitinib 156 Vinorelbine 130 Magnetic Resonance Spectroscopy 110 130-nm albumin-bound paclitaxel 109 Ipilimumab 102 Cetuximab 98 Topotecan 91 Cyclophosphamide 91 tislelizumab 88 Taxes 87 Irinotecan 84 anlotinib 83 Albumin-Bound Paclitaxel 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02504489 2022-09-10

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡